Document is current
Any future updates will be listed below
-
Authors
Ernst, Marielle https://orcid.org/0000-0003-2870-4109
Psychogios, Marios-Nikos
Schlemm, Eckhard
Holodinsky, Jessalyn K.
Kamal, Noreen
Rodt, Thomas
Henningsen, Henning
Kraemer, Christoffer
Thomalla, Götz
Fiehler, Jens
Brekenfeld, Caspar
-
Funding
Funding for this research was provided by:
Universitätsklinikum Hamburg-Eppendorf (UKE)
- License Information
-
More Information
Article History
Received: 14 May 2020
Accepted: 25 June 2020
First Online: 16 July 2020
Conflict of interest
: J.K. Holodinsky and N. Kamal report equity ownership in DESTINE Health Inc. J. Fiehler is the Chief Executive Officer of Eppdata and reports general research support outside the submitted work by the German Ministry of Science and Education, German Ministry of Economy and Innovation, German Research Foundation, European Union, Hamburgische Investitions- und Förderbank, Medtronic, Microvention, Philips, and Stryker and consultancy fees from Boehringer Ingelheim, Acandis, Cerenovus, Covidien, Evasc Neurovascular, MD Clinicals, Medtronic, Medina, Microvention, Penumbra, Route92, Stryker, and Transverse Medical. G. Thomalla reports receiving consulting fees from Acandis; lecture fees from Bayer, Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer, and Daiichi Sankyo and consulting fees and lecture fees from Stryker. M. Ernst, M.-N. Psychogios, E. Schlemm, T. Rodt, H. Henningsen, C. Kraemer and C. Brekenfeld declare that they have no competing interests.
